{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=7", "query": { "intervention": "Peripheral Blood", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 20678, "total_pages": 2068, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T18:27:24.764Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02251548", "title": "A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Leukemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 85, "start_date": "2014-10", "completion_date": "2027-01", "has_results": true, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 9, "location_summary": "Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida + 4 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02251548" }, { "nct_id": "NCT04601155", "title": "Transition of Renal Patients Using AlloSure Into Community Kidney Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Kidney Transplant Rejection" ], "interventions": [ { "name": "AlloSure", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "CareDx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 248, "start_date": "2020-11-19", "completion_date": "2023-10-06", "has_results": false, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 18, "location_summary": "Fairfield, California • Fresno, California • Granada Hills, California + 15 more", "locations": [ { "city": "Fairfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Granada Hills", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04601155" }, { "nct_id": "NCT04286555", "title": "Dietary Approaches to Stop Hypertension for Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 2", "Diabetes", "Diabetes type2", "Type2 Diabetes", "Type 2 Diabetes", "Type II Diabetes", "Hypertension", "High Blood Pressure" ], "interventions": [ { "name": "DASH4D diet", "type": "OTHER" }, { "name": "comparison diet", "type": "OTHER" }, { "name": "higher sodium", "type": "OTHER" }, { "name": "lower sodium", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2021-06-02", "completion_date": "2024-06-17", "has_results": true, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04286555" }, { "nct_id": "NCT02840578", "title": "NK Cell Activity in Smokers Screened for Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 242, "start_date": "2016-12-16", "completion_date": "2018-03-05", "has_results": false, "last_update_posted_date": "2018-05-11", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02840578" }, { "nct_id": "NCT02626715", "title": "Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Hematopoietic Stem Cell Transplant (HSCT)" ], "interventions": [ { "name": "Reduced-Intensity Conditioning Regimen", "type": "DRUG" }, { "name": "Myeloablative Conditioning Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Randy Windreich", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Months", "maximum_age": "26 Years", "sex": "ALL", "summary": "0 Months to 26 Years" }, "enrollment_count": 21, "start_date": "2015-09-04", "completion_date": "2023-04-12", "has_results": true, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02626715" }, { "nct_id": "NCT00834509", "title": "Biomarkers for Obstructive Sleep Apnea", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Obstructive Sleep Apnea (OSA)" ], "interventions": [ { "name": "CPAP", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 181, "start_date": "2008-04", "completion_date": "2015-02-01", "has_results": false, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00834509" }, { "nct_id": "NCT05605899", "title": "Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Large B-cell Lymphoma (LBCL)" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-02-10", "completion_date": "2031-03", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05605899" }, { "nct_id": "NCT04423198", "title": "HEAD Injury Serum Markers and Multi-modalities for Assessing Response to Trauma", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mild Traumatic Brain Injury" ], "interventions": [ { "name": "Cognitive Assessment", "type": "BEHAVIORAL" }, { "name": "Patient Reported Neurological Outcome Assessments", "type": "BEHAVIORAL" }, { "name": "Blood Draw", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE" ], "sponsor": "BRAINBox Solutions Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2020-12-31", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-08-04", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 11, "location_summary": "Kansas City, Kansas • Detroit, Michigan • Rochester, New York + 5 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04423198" }, { "nct_id": "NCT01256398", "title": "Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1" ], "interventions": [ { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "In Vitro-Treated Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-12-14", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 101, "location_summary": "Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01256398" }, { "nct_id": "NCT03420963", "title": "Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Cutaneous Melanoma", "Recurrent Lip and Oral Cavity Carcinoma", "Recurrent Malignant Endocrine Neoplasm", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Male Reproductive System Neoplasm", "Recurrent Malignant Mesothelioma", "Recurrent Malignant Neoplasm of Multiple Primary Sites", "Recurrent Malignant Oral Neoplasm", "Recurrent Malignant Pharyngeal Neoplasm", "Recurrent Malignant Skin Neoplasm", "Recurrent Malignant Soft Tissue Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Thyroid Gland Neoplasm", "Recurrent Malignant Urinary System Neoplasm", "Refractory Cutaneous Melanoma", "Refractory Malignant Bone Neoplasm", "Refractory Malignant Endocrine Neoplasm", "Refractory Malignant Female Reproductive System Neoplasm", "Refractory Malignant Male Reproductive System Neoplasm", "Refractory Malignant Mesothelioma", "Refractory Malignant Neoplasm of Multiple Primary Sites", "Refractory Malignant Oral Neoplasm", "Refractory Malignant Pharyngeal Neoplasm", "Refractory Malignant Skin Neoplasm", "Refractory Malignant Soft Tissue Neoplasm", "Refractory Malignant Solid Neoplasm", "Refractory Malignant Thyroid Gland Neoplasm", "Refractory Malignant Urinary System Neoplasm" ], "interventions": [ { "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Months to 40 Years" }, "enrollment_count": 12, "start_date": "2018-08-31", "completion_date": "2026-02-26", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-11-09T18:27:24.764Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03420963" } ] }